GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Alembic Pharmaceuticals Ltd

Alembic Pharma Q2 FY27 Consolidated Revenue Up 36% to Rs. 2,603.48 Crores

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Nov 2026, 02:31 PM IST  ·  BSE ID: 75a8860b-96ab-4d97-aa29-8b3d5bda9624
View Original BSE Filing (PDF)
💡
In Simple Terms
Alembic Pharma saw its sales jump by 36% and profit increase by 81% in the latest financial quarter.
🤖 AI Summary
  • Alembic Pharmaceuticals' consolidated revenue from operations for Q2 FY27 increased 36% to Rs. 2,603.48 Crores.
  • Profit for Q2 FY27 after non-controlling interests rose 81% year-on-year to Rs. 335.17 Crores.
  • Basic & Diluted Earnings per Share (EPS) for Q2 FY27 was Rs. 17.05, up from Rs. 9.40 in Q2 FY26.
  • Total consolidated income for the quarter ended 30 September 2026 reached Rs. 2,618.59 Crores.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
Rs. 2,603.48 Crores
36.20%
Profit for the Period after non-controlling interests (Q2 FY27)
Rs. 335.17 Crores
81.46%
Earnings per share – Basic & Diluted (Q2 FY27)
Rs. 17.05
81.38%
Total Income (Q2 FY27)
Rs. 2,618.59 Crores
36.60%
Net Worth (as at 30.09.2026)
Rs. 5,950.55 Crores
🏢 How This Affects the Company
📈
Business Impact
The increase in revenue from operations suggests stronger market performance and demand for the company's pharmaceutical products compared to the prior year period. The growth in net profit indicates improved operational efficiency or pricing power.
💰
Financial Impact
The significant rise in profit for the period directly enhances earnings and strengthens the company's financial performance. Improved operating margin also points to better cost management relative to revenue growth.
⚙️
Operational Impact
The higher revenue could imply increased production and sales volumes, which would require efficient supply chain management and manufacturing capacity utilization. Employee benefits expense increased to Rs. 503.75 Crores.
⚠️
Risk Impact
The continued growth in revenue and profit can reduce financial vulnerability. However, increases in finance costs and other expenses warrant continued monitoring of overall cost structures.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the improved financial performance, as consolidated net profit for Q2 FY27 increased to Rs. 335.17 Crores from Rs. 184.71 Crores in Q2 FY26.
🔍
Management Signal
The approval of these unaudited financial results by the Board indicates management's focus on operational execution and profitability.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — assess if revenue and profit growth trends continue.
Any updates on operational expenditure or finance costs in subsequent filings.
Updates on asset held for sale or other exceptional items in future reports.
LOW RISK Strong financial performance and positive growth indicate low immediate risk.
💡 Investor Takeaway
Alembic Pharmaceuticals reported Q2 FY27 consolidated revenue of Rs. 2,603.48 Crores, a 36% increase YoY, with profit after non-controlling interests surging 81% to Rs. 335.17 Crores. The Debt-Equity Ratio stood at 0.25 times for Q2 FY27.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated revenue from operations for Q2 FY27 increased 36% YoY to Rs. 2,603.48 Crores from Rs. 1,910.15 Crores.
  • Profit for the period after non-controlling interests grew 81% YoY to Rs. 335.17 Crores in Q2 FY27 from Rs. 184.71 Crores.

⚠️ Concerns

  • Finance Costs for Q2 FY27 increased by 57.99% YoY to Rs. 38.26 Crores from Rs. 24.23 Crores in Q2 FY26.
  • Other Expenses for Q2 FY27 rose 32.71% YoY to Rs. 850.69 Crores from Rs. 641.00 Crores in Q2 FY26.
📅 Company Track Record
Alembic Pharma's Q1 FY27 consolidated revenue was Rs. 2,149.77 Crores with profit of Rs. 173.07 Crores. Prior period filings also showed robust growth, with Q1 FY27 revenue up 26% and PAT up 12% YoY, establishing a recent trend of strong performance.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Alembic Pharmaceuticals' consolidated revenue for Q2 FY27?
Alembic Pharmaceuticals reported consolidated revenue from operations of Rs. 2,603.48 Crores for the quarter ended 30 September 2026 (Q2 FY27).
What was Alembic Pharmaceuticals' net profit for Q2 FY27?
The consolidated profit for the period after non-controlling interests for Alembic Pharmaceuticals was Rs. 335.17 Crores in Q2 FY27.
How did Alembic Pharmaceuticals' Q2 FY27 revenue compare to the previous year?
Consolidated revenue from operations for Q2 FY27 increased by 36.20% to Rs. 2,603.48 Crores compared to Rs. 1,910.15 Crores in Q2 FY26.
What were the Earnings per Share (EPS) for Alembic Pharmaceuticals in Q2 FY27?
The Basic & Diluted Earnings per Share (EPS) for Alembic Pharmaceuticals was Rs. 17.05 for the quarter ended 30 September 2026 (Q2 FY27).

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.